QSIT At 15: Two Co-Creators Of FDA’s Aging Audit Technique Look Back – And Mull Over Today’s Agency Approach
This article was originally published in The Silver Sheet
Executive Summary
Now that FDA’s Quality System Inspection Technique is 15 years old, is it time for a facelift? Two ex-FDA officials who were part of the FDA team that developed QSIT say the inspectional approach is still relevant, but perhaps for different reasons than were envisioned in 1999. Former QSIT team leader Tim Wells says the technique can serve as “a roadmap to quality system compliance” for medical device manufacturers, yet fellow team member and ex-investigator Denise Dion is concerned about changes the agency has made over the years to how such audits are conducted. In a Q&A with “The Silver Sheet,” the duo also talk about why QSIT was devised in the first place, a struggle by the Office of Regulatory Affairs to keep facility walk-throughs in the technique and whether they believe QSIT will ever be revised, among other topics.
You may also be interested in...
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.
FDA Slaps High Risk Class I Label On Recall Of COVID-19 Diagnostics Made In Uncontrolled Plant
More than 160,000 of the tests were recalled, including 104,900 COVID Test Kits Nonsterile and 61,500 Clean Catch Urine Kits.